MIB-626

Phase 2Small molecule

MMetro International Biotech, LLC

MIB-626 is one of 3 small molecule programs targeting Down Syndrome (DS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Down Syndrome (DS)Not yet recruiting

Coronary Artery Bypass GraftRecruiting

Down Syndrome (DS)Phase 1

Not yet recruiting

Coronary Artery Bypass GraftPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Coronary Artery Bypass Graft

#DrugCompanyPhaseTrials

Cardizem

BBausch Health Americas, Inc.

Approved

1 2

Imdur

OOmnivium

Approved

1 3

MIB-626

MMetro International Biotech, LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Down Syndrome (DS)

NCT07278492

Q1 2029

Phase 2Recruiting

Coronary Artery Bypass Graft

NCT07013591

Clinical

Trials by Indication[1]

COVID-191 trial

Phase 2a MIB-626 vs. Placebo COVID-19

Completed·MMetro International Biotech, LLC·Phase 2·NCT05038488·42 enrolled

Ataxia1 trial

NAD+ Precursor Supplementation in Friedreich's Ataxia

Completed·MMetro International Biotech, LLC·Phase 2·NCT04817111·7 enrolled

Down Syndrome (DS)1 trial

Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People With Down Syndrome

Not yet recruiting·BBrigham and Women's Hospital·Phase 1·NCT07278492·24 enrolled

Alzheimer disease1 trial

A Proof of Concept Trial of a Sirtuin-NAD Activator in Alzheimer's Disease

Completed·BBrigham and Women's Hospital·Preclinical·NCT05040321·22 enrolled

Coronary Artery Bypass Graft1 trial

Randomized Clinical Trial of β Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT07013591·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MIB-626. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MIB-626 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MIB-626. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Metro International Biotech, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMetro International Biotech, LLC

MIB-626

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

COVID-191 trial

Ataxia1 trial

Down Syndrome (DS)1 trial

Alzheimer disease1 trial

Coronary Artery Bypass Graft1 trial

References

Drug Info

Quick Facts

Related News